GuruFocus Premium Membership

Serving Intelligent Investors since 2004. Only 96 cents a day.

Free Trial

Free 7-day Trial
All Articles and Columns »

Weekly Top Insider Buys

June 17, 2013 | About:
guruek

guruek

80 followers
GuruFocus Insider Data, these are the largest insider buys during the past week. The overall trend of insiders is illustrated in the chart below:



Valeant Pharmaceuticals International Inc. (VRX): Director Lloyd Mitchell Segal Bought 3,190 Shares

Director of Valeant Pharmaceuticals International Inc. (VRX) Lloyd Mitchell Segal bought 3,190 shares on 06/12/2013 at an average price of $84.20.

Valeant Pharmaceuticals International Inc. was formerly known as Biovail Corporation. Valeant Pharmaceuticals International Inc. has a market cap of $26.11 billion; its shares were traded at around $84.20 with a P/E ratio of 889.10 and P/S ratio of 6.90.

On May 2, 2013, Valeant Pharmaceuticals International Inc announces first quarter financial results for 2013. Valeant's total revenues were $1.068 billion, up 25% compared to the first quarter of 2012, and product revenues were $1.039 billion, up 38% versus the year-ago quarter.

Director Norma Ann Provencio sold 6,000 shares of VRX stock on 06/11/2013 at the average price of $85.26. Norma Ann Provencio owns at least 171,860 shares after this. The price of the stock has decreased by 1.24% since.

Vornado Realty Trust (VNO): CFO Stephen W. Theriot Bought 3,100 Shares

CFO of Vornado Realty Trust (VNO) Stephen W. Theriot bought 3,100 shares on 06/10/2013 at an average price of $82.85.

Vornado Realty Trust is a fully integrated real estate investment trust and conducts its business through Vornado Realty L. Vornado Realty Trust has a market cap of $15.43 billion; its shares were traded at around $82.85 with a P/E ratio of 122.00 and P/S ratio of 6.80. The dividend yield of Vornado Realty Trust stocks is 3.40%. Vornado Realty Trust had an annual average earnings growth of 7.7% over the past five years.

May 6, 2013 Vornado Realty Trust filed its Form 10-Q for the quarter ended March 31, 2013 reported net income attributable to common shareholders for the quarter ended March 31, 2013 was $232.0 million, or $1.24 per diluted share, compared to $233.7 million, or $1.25 per diluted share for the quarter ended March 31, 2012. Net income for the quarters ended March 31, 2013 and 2012 include $202.8 million and $56.5 million, respectively, of net gains on sale of real estate, and $5.2 million and $8.9 million, respectively, of real estate impairment losses. In addition, the quarters ended March 31, 2013 and 2012 include certain other items that affect comparability, which are listed in the table below. Adjusting net income attributable to common shareholders for net gains on sale of real estate, real estate impairment losses and the items in the table below, net of amounts attributable to noncontrolling interests, net income attributable to common shareholders for the quarters ended March 31, 2013 and 2012 was $72.2 million and $47.1 million, or $0.39 and $0.28 per diluted share, respectively.

President VNO/Smith Division Mitchell N. Schear sold 14,792 shares of VNO stock on 12/21/2012 at the average price of $79.99. Mitchell N. Schear owns at least 54,086 shares after this. The price of the stock has increased by 3.58% since.

For the complete list of stocks that were bought by their company executives, go to: Insider Buys.
  • CEO Buys, CFO Buys: Stocks that are bought by their CEO/CFOs.
  • Insider Cluster Buys: Stocks that multiple company officers and directors have bought.
  • Double Buys:: Companies that both Gurus and Insiders are buying
  • Triple Buys: Companies that both Gurus and Insiders are buying, and Company is buying back.

» Take a Free Trial of Premium Membership


Rating: 4.7/5 (3 votes)

Comments

Please leave your comment:


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK